ArticleHuman vaccines & immunotherapeutics2015
Current advances and challenges in the development of Acinetobacter vaccines.
Article in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 58 citations in OpenAlex.
- Design a multi-epitope vaccine candidate against Acinetobacter baumannii using advanced computational methods.AMB Express · 2025Article
- Development of a multi-epitope vaccine against Acinetobacter baumannii: A comprehensive approach to combating antimicrobial resistance.PloS one · 2025Article
- AnCurrent computer-aided drug design · 2025Article
- Review
- Development of acute Pseudomonas aeruginosa and Acinetobacter baumannii lung mono-challenge models in mice using oropharyngeal aspiration.Access microbiology · 2024Article
- Two peptides derivate from Acinetobacter baumannii outer membrane protein K as vaccine candidates: a comprehensive in silico study.BMC research notes · 2023Article
- The Prevalence of Multidrug-ResistantVaccines · 2023Review
- Protective Capacity of Monoclonal Antibodies against Acinetobacter baumannii K9 Capsular Polysaccharide.Microbiology spectrum · 2023Article
- Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance.Chemical reviews · 2022Review
- Evaluation the reactivity of a peptide-based monoclonal antibody derived from OmpA with drug resistant pulsotypes of Acinetobacter baumannii as a potential therapeutic approach.Annals of clinical microbiology and antimicrobials · 2022Article
- Review
- Facing the challenges of multidrug-resistantHuman vaccines & immunotherapeutics · 2021Article
- Synthetic Pseudaminic-Acid-Based Antibacterial Vaccine Confers Effective Protection againstACS central science · 2021Article
- Mapping Global Prevalence ofVaccines · 2021Review
- Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection.Scientific reports · 2021Article
- The impact of human vaccines on bacterial antimicrobial resistance. A review.Environmental chemistry letters · 2021Review
- A Multiepitope Peptide, rOmp22, Encapsulated in Chitosan-PLGA Nanoparticles as a Candidate Vaccine AgainstInternational journal of nanomedicine · 2021Article
- Outer membrane protein A (OmpA) as a potential therapeutic target for Acinetobacter baumannii infection.Journal of biomedical science · 2020Review
- Host Innate Immune Responses toFrontiers in cellular and infection microbiology · 2020Review
- Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is a major cause of healthcare-associated infections worldwide with high morbidity and mortality. The clinical treatment of A. baumannii infections has become increasingly difficult because of the rapid emerging of multidrug and extremely drug resistant strains. Thus, there is an urgent need for the development of novel intervention strategies to combat this multidrug-resistant pathogen. Vaccine is one of the most effective medical measures for infection control and is likely to overcome the development of multidrug resistance by A. baumannii. Here we discussed the recent advances and potential challenges in development of A. baumannii vaccines with a focus on the 3 most important steps in the preclinical vaccine development: antigen selection, immune correlates of protection, and animal models for efficacy evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.